Jobs
-
According to Sunovion Pharmaceuticals, data from a year-long clinical trial comparing the safety of Brovana arformoterol tartrate inhalation solution versus placebo in patients with moderate-to-severe COPD show no increased risk of exacerbations or death due… Read more . . .
-
Pearl Therapeutics has announced the initiation of a Phase 3 program called PINNACLE for its PT003 glycopyrrolate/formoterol fumarate metered dose inhaler for patients with moderate-to-severe COPD. The program will include two studies involving more than… Read more . . .
-
According to Aegis Therapeutics, the company has been granted US Patent No. 8,440,631 for fast-acting formulations of triptans for the treatment of migraines. The patent is the second for Aegis’s triptan nasal sprays using its… Read more . . .
-
The European Patent Office will grant Insmed Incorporated EU Patent No. 1909759 for Arikace liposomal amikacin for inhalation, according to Insmed. The composition of matter patent, titled “Sustained release of anti-infective aminoglycosides,” covers formulations of… Read more . . .
-
Elan Corporation has announced that it will pay Theravance $1 billion for a 21% participation interest in future royalty payments from sales of Breo (Relvar) Ellipta, Anoro Ellipta, MABA ‘081 bifunctional muscarinic antagonist-beta2 agonist monotherapy,… Read more . . .
-
Vectura has announced that it has partnered with Chinese pharmaceutical company Tianjin KingYork Group and Hong Kong private equity investor Zendex Bio Strategy to create Tianjin Kinnovata Pharmaceutical Company Limited (“Kinnovata”). The new company will… Read more . . .
-
The FDA has approved GSK and Theravance’s Breo Ellipta fluticasone furoate/vilanterol inhalation powder for the treatment of COPD). The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted to recommend approval of Breo Ellipta in April 2013.… Read more . . .
-
A UK innovation agency, the Technology Strategy Board, has awarded Team Consulting a grant to fund an 8-month feasibility test of its Occoris inhaler “engine” technology, the company said. According to Team, the Occoris engine,… Read more . . .
-
Alexza Pharmaceuticals and Teva Pharmaceuticals USA have announced that Teva will market Adasuve loxapine inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in the US. The FDA approved Adasuve… Read more . . .
-
Contract research organization MedPharm has announced the opening of a new GLP laboratory at its Guildford, UK headquarters. According to the company, “The additional space will provide further capacity for MedPharm’s proprietary in vitro/ex vivo… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland